Australian Influencer Thought She Was 'Going To Die' After Overdosing On 'Miracle' Weight Loss Drug Ozempic

Roxy Jacenko, an Australian influencer, revealed that she was rushed to the hospital following an overdose of the diabetes drug Ozempic, Pedestrian reported. 

Jacenko admitted in an interview with The Daily Telegraph that she had taken Ozempic, popularly used for weight loss and heard among celebrities like Amy Schumer and Kim Kardashian.

Jacenko revealed her struggle with weight gain after undergoing hormone therapy for her breast cancer diagnosis, leading her to seek Ozempic. Despite her doctor’s refusal, she managed to obtain the drug.

"I took the 1ml because it was it was all I could get. I was like a junkie. I was like a proper junkie,” she recalled.

See Also: Could Medical Cannabis Be The Answer For Fibromyalgia? Here’s What New Study Found

The influencer went into shock following the overdose, experiencing uncontrollable vomiting and shaking, prompting her to call an ambulance. Jacenko felt she was “going to die”.

Now she warns her followers about the risks of using Ozempic for weight loss.

Ozempic, a type 2 diabetes treatment, is not intended for weight loss. However, it can inhibit appetite and slow down the movement of food in the gut

Read Next: Contemporary art pieces have shown miniscule correlation to other assets during crises. However, not all are created equal. Click here to invest in pieces experts agreed could outperform the market.

Image By Natalia Varlei On Shutterstock


Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMediaGeneralDiabetesOzempicweightloss
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!